R A Rudick

Summary

Affiliation: Cleveland Clinic Foundation
Country: USA

Publications

  1. ncbi Use of the Multiple Sclerosis Functional Composite to predict disability in relapsing MS
    R A Rudick
    Mellen Center for Multiple Sclerosis Treatment and Research, Department of Neurology, Cleveland Clinic Foundation, OH 44195, USA
    Neurology 56:1324-30. 2001
  2. ncbi Eight-year follow-up study of brain atrophy in patients with MS
    E Fisher
    Whitaker Biomedical Imaging Laboratory, The Cleveland Clinic Foundation, OH 44195, USA
    Neurology 59:1412-20. 2002
  3. ncbi Assessing disability progression with the Multiple Sclerosis Functional Composite
    R A Rudick
    Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic, Cleveland, OH 44106, USA
    Mult Scler 15:984-97. 2009
  4. ncbi Estimating long-term effects of disease-modifying drug therapy in multiple sclerosis patients
    R A Rudick
    Department of Neurology, Mellen Center for Multiple Sclerosis Treatment and Research, The Cleveland Clinic Foundation, OH 44195, USA
    Mult Scler 11:626-34. 2005
  5. ncbi Change in quality of life in patients with relapsing-remitting multiple sclerosis over 2 years in relation to other clinical parameters: results from a trial of intramuscular interferon {beta}-1a
    D M Miller
    Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic Foundation, U 10 9500 Euclid Avenue, Cleveland, OH 44118, USA
    Mult Scler 17:734-42. 2011
  6. ncbi Intramuscular interferon beta-1a therapy in patients with relapsing-remitting multiple sclerosis: a 15-year follow-up study
    R A Bermel
    Department of Neurology, Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic, Cleveland, OH 44195, USA
    Mult Scler 16:588-96. 2010
  7. ncbi Cerebrospinal fluid abnormalities in a phase III trial of Avonex (IFNbeta-1a) for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group
    R A Rudick
    Mellen Center for Multiple Sclerosis Treatment and Research, Department of Neurology, The Cleveland Clinic Foundation, OH 44106, USA
    J Neuroimmunol 93:8-14. 1999
  8. ncbi Gender effects on intramuscular interferon beta-1a in relapsing-remitting multiple sclerosis: analysis of 1406 patients
    R A Rudick
    Mellen Center for Treatment and Research Neurological Institute, The Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Mult Scler 17:353-60. 2011
  9. ncbi Effect of statins on clinical and molecular responses to intramuscular interferon beta-1a
    R A Rudick
    Mellen Center for Treatment and Research in Multiple Sclerosis, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    Neurology 72:1989-93. 2009
  10. ncbi Quantification of self-recognition in multiple sclerosis by single-cell analysis of cytokine production
    C M Pelfrey
    Department of Neurosciences, Lerner Research Institute, Department of Neurology, Mellen Center for Multiple Sclerosis Research, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    J Immunol 165:1641-51. 2000

Detail Information

Publications26

  1. ncbi Use of the Multiple Sclerosis Functional Composite to predict disability in relapsing MS
    R A Rudick
    Mellen Center for Multiple Sclerosis Treatment and Research, Department of Neurology, Cleveland Clinic Foundation, OH 44195, USA
    Neurology 56:1324-30. 2001
    ..To determine whether the MS Functional Composite (MSFC) can predict future disease progression in patients with relapsing remitting MS (RR-MS)...
  2. ncbi Eight-year follow-up study of brain atrophy in patients with MS
    E Fisher
    Whitaker Biomedical Imaging Laboratory, The Cleveland Clinic Foundation, OH 44195, USA
    Neurology 59:1412-20. 2002
    ..The specific goals of this study were to determine if brain atrophy is related to subsequent disability status and to identify MRI correlates of atrophy progression...
  3. ncbi Assessing disability progression with the Multiple Sclerosis Functional Composite
    R A Rudick
    Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic, Cleveland, OH 44106, USA
    Mult Scler 15:984-97. 2009
    ..However, the clinical meaning of an MSFC Z-score change is not obvious. This study instead used MSFC component data to define a patient-specific disease progression event...
  4. ncbi Estimating long-term effects of disease-modifying drug therapy in multiple sclerosis patients
    R A Rudick
    Department of Neurology, Mellen Center for Multiple Sclerosis Treatment and Research, The Cleveland Clinic Foundation, OH 44195, USA
    Mult Scler 11:626-34. 2005
    ..The paucity of data on the long-term treatment of patients with MS may be aided by applying these or similar methods to vigorously followed cohorts of patients...
  5. ncbi Change in quality of life in patients with relapsing-remitting multiple sclerosis over 2 years in relation to other clinical parameters: results from a trial of intramuscular interferon {beta}-1a
    D M Miller
    Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic Foundation, U 10 9500 Euclid Avenue, Cleveland, OH 44118, USA
    Mult Scler 17:734-42. 2011
    ....
  6. ncbi Intramuscular interferon beta-1a therapy in patients with relapsing-remitting multiple sclerosis: a 15-year follow-up study
    R A Bermel
    Department of Neurology, Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic, Cleveland, OH 44195, USA
    Mult Scler 16:588-96. 2010
    ....
  7. ncbi Cerebrospinal fluid abnormalities in a phase III trial of Avonex (IFNbeta-1a) for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group
    R A Rudick
    Mellen Center for Multiple Sclerosis Treatment and Research, Department of Neurology, The Cleveland Clinic Foundation, OH 44106, USA
    J Neuroimmunol 93:8-14. 1999
    ..The objectives of the current study were to determine: (a) whether CSF abnormalities in MS patients correlated with disease or MRI characteristics, and (b) effects of IFNbeta-1a therapy on these CSF abnormalities...
  8. ncbi Gender effects on intramuscular interferon beta-1a in relapsing-remitting multiple sclerosis: analysis of 1406 patients
    R A Rudick
    Mellen Center for Treatment and Research Neurological Institute, The Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Mult Scler 17:353-60. 2011
    ..We aimed to evaluate effects of gender on efficacy and safety of intramuscular (IM) interferon beta (IFNβ)-1a in patients with relapsing-remitting MS (RRMS) or clinically isolated syndromes (CIS) characteristic of early MS...
  9. ncbi Effect of statins on clinical and molecular responses to intramuscular interferon beta-1a
    R A Rudick
    Mellen Center for Treatment and Research in Multiple Sclerosis, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    Neurology 72:1989-93. 2009
    ..Findings from a small clinical study suggested that statins may counteract the therapeutic effects of interferon beta (IFNbeta) in patients with relapsing-remitting multiple sclerosis (RRMS)...
  10. ncbi Quantification of self-recognition in multiple sclerosis by single-cell analysis of cytokine production
    C M Pelfrey
    Department of Neurosciences, Lerner Research Institute, Department of Neurology, Mellen Center for Multiple Sclerosis Research, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    J Immunol 165:1641-51. 2000
    ..The essential absence of uncommitted Th0 cells producing both cytokines may explain why therapeutic strategies that aim at the induction of immune deviation show little efficacy in the established disease...
  11. ncbi Optimal reference population for the multiple sclerosis functional composite
    R J Fox
    Mellen Center for Multiple Sclerosis, Department of Neurology, Cleveland, OH, USA
    Mult Scler 13:909-14. 2007
    ..These results have significant implications to sample size estimates for longitudinal clinical studies and therapeutic trials...
  12. ncbi Disease-modifying drugs for relapsing-remitting multiple sclerosis and future directions for multiple sclerosis therapeutics
    R A Rudick
    Mellen Center for Multiple Sclerosis Treatment and Research, Department of Neurology, Cleveland Clinic Foundation, Ohio 44106, USA
    Arch Neurol 56:1079-84. 1999
    ..Major issues confronting experimental MS therapeutics are discussed...
  13. ncbi Contemporary immunomodulatory therapy for multiple sclerosis
    R A Rudick
    Department of Neurology, Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    J Neuroophthalmol 21:284-91. 2001
    ..There is a tendency toward early diagnosis and treatment based on the hypothesis that treatment effectiveness declines with advancing disease...
  14. ncbi Evolving concepts in the pathogenesis of multiple sclerosis and their therapeutic implications
    R A Rudick
    Mellen Center for Multiple Sclerosis Treatment and Research Department of Neurology, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    J Neuroophthalmol 21:279-83. 2001
    ..These concepts have important implications related to the diagnosis, methods for patient follow-up, type and timing of disease therapy, and the testing of neuroprotective drugs in MS...
  15. ncbi Multiple sclerosis: chemokine receptor expression on circulating lymphocytes in correlation with radiographic measures of tissue injury
    R J Fox
    Department of Neurology, Mellen Center, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Mult Scler 14:1036-43. 2008
    ..This observation suggests a CKR "set-point" within individuals, which might relate to inflammatory injury in MS. We evaluated the correlation between CKR levels and magnetic resonance imaging (MRI) measures of disease activity...
  16. ncbi Longitudinal single-cell cytokine responses reveal recurrent autoimmune myelin reactivity in relapsing--remitting multiple sclerosis patients
    I R Moldovan
    Department of Neurosciences, Cleveland Clinic Foundation, Cleveland, OH 44195 0001, USA
    Mult Scler 11:251-60. 2005
    ..This study also reveals the extremely dynamic nature of the immune reactivity to numerous regions of myelin, which can fluctuate dramatically over time. Such fluctuation could hamper the efficacy of antigen-based therapies for MS...
  17. ncbi Natalizumab reduces visual loss in patients with relapsing multiple sclerosis
    L J Balcer
    Department of Neurology, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
    Neurology 68:1299-304. 2007
    ....
  18. ncbi Axonal loss in normal-appearing white matter in a patient with acute MS
    C Bjartmar
    Department of Neurosciences, Lerner Research Institute, Cleveland Clinic Foundation, OH 44195, USA
    Neurology 57:1248-52. 2001
    ..Axonal number and appearance was normal in ascending sensory tracts. CONCLUSIONS: These studies confirm axonal degeneration in the absence of myelin loss as one histopathologic correlate to abnormal MR findings in patients with MS...
  19. ncbi The multiple sclerosis functional composite: a new clinical outcome measure for multiple sderosis trials
    R A Rudick
    Department of Neurology, Mellen Center for Multiple Sclerosis Treatment and Research, The Cleveland Clinic Foundation, Ohio, USA
    Mult Scler 8:359-65. 2002
    ..The studies in aggregate indicate that MSFC and MSFC change are clinically meaningful, and that MSFC has substantial advantages over alternative clinical outcome measures for MS clinical trials...
  20. ncbi Benefit of interferon beta-1a on MSFC progression in secondary progressive MS
    J A Cohen
    Mellen Center for Multiple Sclerosis Treatment and Research, Department of Neurology, Cleveland Clinic Foundation, OH 44195, USA
    Neurology 59:679-87. 2002
    ..Studies of other IFNbeta preparations in secondary progressive MS (SPMS) yielded conflicting results. This study was undertaken to determine whether IFNbeta-1a slowed disease progression in SP-MS...
  21. ncbi The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL
    P A Calabresi
    Johns Hopkins Multiple Sclerosis Center, Baltimore, MD, USA
    Neurology 69:1391-403. 2007
    ..To determine the incidence and clinical effects of antibodies that develop during treatment with natalizumab...
  22. ncbi Low-contrast letter acuity testing captures visual dysfunction in patients with multiple sclerosis
    M L Baier
    Center for Research Methodology and Biometrics, Cooper Institute, 14023 Denver West Parkway, 100, Golden, CO 80401, USA
    Neurology 64:992-5. 2005
    ..To evaluate concurrent and predictive validity for low-contrast letter acuity (L-CLA) testing as a candidate visual component for the Multiple Sclerosis Functional Composite (MSFC)...
  23. ncbi Rate of brain atrophy in relapsing MS decreases during treatment with IFNbeta-1a
    M Hardmeier
    MS MRI Evaluation Centre Basel, University Hospitals Basel, Switzerland
    Neurology 64:236-40. 2005
    ..The atrophy rate reduction observed after treatment month 4 may reflect a beneficial but partial effect of interferon beta-1a and was sustained over the 3-year study period...
  24. ncbi Repeated assessment of neuropsychological deficits in multiple sclerosis using the Symbol Digit Modalities Test and the MS Neuropsychological Screening Questionnaire
    R H B Benedict
    School of Medicine, State University of New York at Buffalo, Buffalo, New York, USA
    Mult Scler 14:940-6. 2008
    ....
  25. ncbi Long-term effects of intravenous high dose methylprednisolone pulses on bone mineral density in patients with multiple sclerosis
    M Zorzon
    Department of Clinical Medicine and Neurology, University of Trieste, Cattinara Hospital, Trieste, Italy
    Eur J Neurol 12:550-6. 2005
    ..BMD should be monitored in patients with MS, regardless of the use of methylprednisolone...
  26. ncbi T-cells in the cerebrospinal fluid express a similar repertoire of inflammatory chemokine receptors in the absence or presence of CNS inflammation: implications for CNS trafficking
    P Kivisakk
    Department of Neurosciences, Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Clin Exp Immunol 129:510-8. 2002
    ..Through interactions with its ligands, CXCR3 is proposed to mediate retention of T-cells in the inflamed CNS...